1006 results about "Gene Modification" patented technology

The invention relates to a gene modified cell and a method for producing fucosyllactose by using the gene modified cell, in particular to a saccharomyces cerevisiae gene modified cell and application thereof, and belongs to the technical field of biological gene engineering. The present invention provides a genetically modified cell comprising a recombinant nucleic acid sequence encoding a polypeptide having an [alpha]-1, 2-fucosyltransferase polypeptide ([alpha]-1, 2-fucosyltransferase) activity. The alpha-1, 2-fucosyltransferase polypeptide includes, but is not limited to, polypeptides having at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99% and 100% identical amino acid sequences with the amino acid sequences of SEQ ID NO: 1-25. According to the gene modified cell, the fucosyllactose synthesis capability of an original strain is improved.

The invention relates to a gene modified cell and a method for producing fucosyllactose by using the gene modified cell, in particular to a kluyveromyces kluyveromyces gene modified cell and application thereof, and belongs to the technical field of biological gene engineering. The present invention provides a genetically modified cell comprising a recombinant nucleic acid sequence encoding a polypeptide having an [alpha]-1, 2-fucosyltransferase polypeptide ([alpha]-1, 2-fucosyltransferase) activity. The alpha-1, 2-fucosyltransferase polypeptide includes, but is not limited to, polypeptides having at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99% and 100% identical amino acid sequences with the amino acid sequences of SEQ ID NO: 1-25. According to the gene modified cell, the fucosyllactose synthesis capability of an original strain is improved.

The invention discloses a construction method and application of a gene modified mesenchymal stem cell. The construction method comprises the following steps: constructing a recombinant lentivirus carrying PD-L1 and ICAM1 genes; the recombinant lentivirus carrying the PD-L1 gene and the ICAM1 gene is transfected with mesenchymal stem cells, and the mesenchymal stem cells are screened by puromycin, so that an engineered mesenchymal stem cell strain modified by the PD-L1 gene and the ICAM1 gene is obtained; the mesenchymal stem cells provided by the invention are modified by engineering genes of PD-L1 and ICAM1, and are screened by puromycin to obtain a mesenchymal stem cell strain capable of stably and highly expressing the genes of PD-L1 and ICAM1; after the mesenchymal stem cells highly expressing the PD-L1 and ICAM1 genes are intravenously injected into an autoimmune hepatitis animal model, the autoimmune hepatitis symptom can be remarkably relieved, the liver injury degree can be reduced, the expression of inflammatory factors can be regulated, the inflammatory reaction can be inhibited, and the obvious curative effect can be achieved.

The present disclosure provides a recombinant yeast cell for making ethanol. The recombinant yeast cell comprises a first genetic modification to increase an ethanol yield in the recombinant yeast cell when compared to a parental yeast cell. The recombinant yeast cell also comprises a second genetic modification capable of increasing pyruvate decarboxylase activity in the recombinant yeast cell when compared to the parental yeast cell. The parental yeast cell lacks the first genetic modification and the second genetic modification. The present disclosure also provides methods for making the recombinant yeast cell as well processes for using the recombinant yeast cell to make ethanol.

The present invention relates to a genetically modified porcine cell, a genetically modified porcine organ and a genetically modified pig comprising a genomic insertion of a CD46 expression sequence. The present invention also relates to methods for producing such genetically modified porcine cell, genetically modified porcine organ and genetically modified pig.

Systems and methods for targeted gene modification, targeted insertion, perturbation of gene transcripts, and nucleic acid editing. Novel nucleic acid targeting systems comprise components of CRISPR systems and non-LTR retrotransposon elements.

The present invention relates to ARP2 of plant stigma cells; the invention relates to application of Ca < 2 + > transport capacity damage of homologous genes 1 and 1 in breaking through reproduction isolation of plants. According to the method for breaking through the plant reproductive isolation, a foundation is laid for further research on the relationship of small peptides for regulating and controlling reproductive isolation calcium signals through co-receptors, and a simple and effective target is provided for gene modification for breaking through the reproductive isolation.

The invention discloses bacillus subtilis with high yield of surfactin, a related enzyme mutant and a preparation method of the bacillus subtilis, the bacillus subtilis is obtained by a gene modification method and can produce the surfactin with high yield, and the highest yield can reach 9.4 g / L; the invention also provides key enzyme mutants participating in surfactin synthesis in the bacillus subtilis, and the key enzyme mutants comprise a biotin carboxylase IdeHA mutant, a biotin carboxylase accBC mutant, an enoyl reductase FabI mutant, a malonyl transferase FabD mutant and a dihydrolipoyl dehydrogenase IPdU mutant. The key enzyme mutants comprise a biotin carboxylase IdeHA mutant, a biotin carboxylase accBC mutant, an enoyl reductase FabI mutant, a malonyl transferase FabD mutant and a dihydrolipoyl dehydrogenase IPdU mutant. The bacillus subtilis for high-yield surfactin and the preparation method thereof disclosed by the invention are beneficial to realizing industrial production and commercial application of the surfactin.

The present invention provides a non-human animal expressing a human or chimeric (e.g., humanized) GDF8 protein and methods of use thereof.

Provided in the present invention are a non-human animal expressing a human or chimeric (e.g. humanized) CFB protein and a use method thereof. Further provided in the present invention are a non-human animal genome, a humanized CFB gene, and a cell, tissue, organ or non-human animal containing the non-human animal genome and the humanized CFB gene. The non-human animal obtained by the present application successfully expresses the human or humanized CFB protein, wherein the protein can be cleaved by CFD, bind to C3b, and achieve a similar effect as in a human body. In addition, the non-human animal obtained in the present application has a complete renal function state and normal blood biochemical indexes. Even more rarely, potential diseases known in the prior art which have been observed in some other transgenic mice do not occur in the non-human animal.

The invention belongs to the technical field of stem cell culture and exosome extraction, and provides an RELM beta pre-activated stem cell outer vesicle with high anti-inflammatory and anti-fibrosis activity. According to the method, the mesenchymal stem cells are subjected to hunger culture after being adhered to the wall and then are continuously cultured by a complete culture medium containing RELM beta factors, then supernate is collected, and the exovesicles are obtained through separation. In the preparation process of the extracellular vesicles, the paracrine function of MSC cells is promoted by the RELM beta, the secretion of anti-inflammatory and anti-fibrosis active factors is obviously activated, and the generation of the extracellular vesicles with enhanced anti-inflammatory and anti-fibrosis effects is promoted. Gene modification is not involved, toxic biochemical reagents or materials are not added, exogenous operation steps are simple and convenient, clinical application is guaranteed through sterile operation, no RELM beta residues exist after extracellular vesicle extraction, and the method is safe, non-toxic and effective.

Genetically modified cells that are compatible with multiple subjects, e.g., universal donor cells, and methods of generating said genetic modified cells are provided herein. The universal donor cells comprise at least one genetic modification within or near at least one gene that encodes a survival factor, wherein the genetic modification comprises an insertion of a polynucleotide encoding a tolerogenic factor. The universal donor cells may further comprise at least one genetic modification within or near a gene that encodes one or more MHC-I or MHC-II human leukocyte antigens or a component or a transcriptional regulator of a MHC-I or MHC-II complex, wherein said genetic modification comprises an insertion of a polynucleotide encoding a second tolerogenic factor.

In one aspect, the disclosure relates to a gene modification tool that fuses a Cas protein with a polymerase. This DSB-independent approach utilizes a DNA-RNA chimeric prime-editor-like guide RNAs (chimeric pegRNAs or cpegRNAs) to enable programmable DNA sequence replacement or excision at endogenous human genomic sites. The Cas9 and RNA portion of cpegRNA helps with targeting a gene, while the DNA portion of cpegRNA is used as a template by the polymerase to repair. Furthermore, the disclosed method can be used to introduce large DNA modifications in the genome.

The invention belongs to the technical field of biology, and particularly relates to a genetically modified mesenchymal stem cell as well as a preparation method and application thereof. The invention relates to a gene modified mesenchymal stem cell, the gene modified mesenchymal stem cell is a mesenchymal stem cell of an over-expression SIRT6 gene, and the acquisition number of the SIRT6 on NCBI (National Center of Biotechnology Information) is NM001193285. The invention finds that SIRT6 is helpful for delaying the cell senescence process and obviously improving the anti-senescence capability of cells by regulating senescence-related genes and proteins.

Provided herein are compositions and methods for use in challenging pathogenic bacteria on plants. Optional features include modification of a donor bacteria to include exogenous nucleic acids encoding for conjugation machinery and gene modification components, such as guide sequence for use in CRISPR. The compositions and methods provided herein can be used for delivery to a wide variety of crops and for targeting one or more pathogens.

The invention relates to a Kluyveromyces cerevisiae gene modified cell containing GDP-mannose dehydratase polypeptide, which can be applied to synthesis of human milk oligosaccharide, and belongs to the field of synthetic biology. According to the technical scheme, the gene modified cell comprises a recombinant nucleic acid sequence for coding a polypeptide with GDP-mannose dehydratase polypeptide (GDP-mannose dehydratase polypeptide) activity. The polypeptide capable of catalyzing the conversion of GDP-mannose into GDP-4-keto-6-deoxymannose comprises a polypeptide of which the amino acid sequence is at least 70%, 75%, 80%, 85%, 90%, 95%, 99% and 100% identical to the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 2 and / or the amino acid sequence of polypeptides M1-M13, wherein the amino acid sequence of the polypeptide is at least 70%, 75%, 80%, 85%, 90%, 95%, 99% and 100% identical to the amino acid sequence of the polypeptides M1-M13. The invention provides a kluyveromyces kluyveromyces genetically modified cell with fucosyllactose synthesis activity.

The invention relates to a genetically modified cell, and belongs to the technical field of biological genetic engineering. The invention provides a genetically modified cell, which contains a heterologous nucleic acid sequence of an alpha-1, 3-fucosyltransferase polypeptide. The alpha-1, 3-fucosyltransferase polypeptide further comprises but is not limited to derived polypeptides M1-M21 of the polypeptide with the amino acid sequence as shown in SEQ ID NO: 1, and compared with the polypeptide as shown in SEQ ID NO: 1, the 3-FL catalytic synthesis capability of the derived polypeptides and the specificity of a catalytic substrate are both improved.

The invention provides an Escherichia coli gene modification method for improving the proportion of plasmid superhelix monomers and a product and application thereof, the method comprises the following steps: knocking out two DNA sequences in a genome of host Escherichia coli by adopting a CRISPR / Cas9 gene editing system, the DNA sequences comprising a recA + gene coding sequence and a recF + gene coding sequence; the nucleotide sequence from the 5'end to the 3 'end of the recA + gene coding sequence is as shown in SEQ ID NO.1, and the nucleotide sequence from the 5' end to the 3 'end of the recF + gene coding sequence is as shown in SEQ ID NO.2. When the escherichia coli engineering strain prepared by the method is used for producing plasmids, the generation of plasmid polymers can be remarkably reduced, and the superhelix monomer proportion of the plasmids can be increased.

The invention discloses a production method of fucosylated oligosaccharide. The core of the method is as follows: the GDP-D-rhamnose is converted into the GDP-L-fucose by using the GDP-D-rhamnose-3, 5-epimerase; the GDP-D-rhamnose is obtained by converting the GDP-D-mannose-4, 6-dehydratase and the GDP-4-keto-6-deoxy D-mannose reductase by taking the GDP-D-mannose as a substrate, and the GDP-D-rhamnose is obtained by taking the GDP-D-mannose as a substrate. The invention relates to a method for producing a fucosylated oligosaccharide, which is characterized in that a GDP-D-mannose-4, 6-dehydratase, a GDP-4-keto-6-deoxyD-mannose reductase, a GDP-D-rhamnose-3, 5-epimerase and a fucosyltransferase are expressed in a genetically modified host cell, and the fucosylated oligosaccharide can be produced by the way mentioned above.

Provided herein are genetically modified hematopoietic cells with reduced expression or activity of: (i) one or more CRL5 complex genes, and / or (ii) one or more genes orthogonal to the CRL5 complex, that exhibit improved therapeutic potential compared to wild-type hematopoietic cells, as well as methods of generating and using genetically modified hematopoietic cells for the treatment of a disease, such as cancer.

A composition for genetic editing of a hydroxyacid oxidase 1 (HAO1) gene, comprising: (a) a messenger RNA (mRNA) encoding a Cas12i2 polypeptide, (b) a guide RNA (gRNA) targeting the HAO1 gene; and (c) lipid excipients, which optionally form lipid nanoparticles. Also provided herein are methods for genetic modification of the HAO1 gene in host cells with the composition provided herein.

The present disclosure provides engineered bacterial cells having one or more genetic modifications that result in increased production of expression products, such as increased production of plasmids with reduced occurrence of plasmid concatemers or multimers. Also disclosed herein are expression systems for product manufacturing in media having reduced antibiotic concentration, as well as methods of making cells for use in the expression systems. The cells and expression systems increase the growth rate and production yields of biomolecules produced within the host bacterial host cells without the use of antibiotics, and can produce the product with little to no endotoxins present.

The present invention relates to a method for genetic manipulation of immune cells or progenitors thereof, by lipid nanoparticles delivery of a gene modifying agent to cells.

The invention discloses a construction method and application of a chlamydomonas reinhardtii-sourced high-sweetness protein variant engineering algal strain, the construction method comprises the following steps: carrying out gene modification on sweeteners Thaumatin and Brazzein, optimizing preference codons of chlamydomonas reinhardtii to synthesize CrThaumatin and CrBrazzein encoding genes, cloning the encoding genes into an expression vector pGM6, introducing the recombinant expression vector into a chlamydomonas reinhardtii wild-type chlamydomonas sp. Algal strain, and carrying out high-sweetness protein variant engineering algal strain of the chlamydomonas reinhardtii-sourced high-sweetness protein variant engineering algal strain of the chlamydomonas reinhardtii. And screening by using a paromomycin resistance marker carried by the expression vector to successfully obtain an engineering algal strain. According to the present invention, the engineering strain is subjected to fermentation production to obtain the dry and stable Chlamydomonas reinhardtii powder rich in the target sweet protein, and the protein purification oral test results show that the sweet taste of the Chlamydomonas reinhardtii powder is 3-5 times of the sweet taste of the natural Thaumatin and Brazzein protein;

The present disclosure provides a DNA-targeting RNA that comprises a targeting sequence and, together with a modifying polypeptide, provides for site-specific modification of a target DNA and / or a polypeptide associated with the target DNA. The present disclosure further provides site-specific modifying polypeptides. The present disclosure further provides methods of site-specific modification of a target DNA and / or a polypeptide associated with the target DNA The present disclosure provides methods of modulating transcription of a target nucleic acid in a target cell, generally involving contacting the target nucleic acid with an enzymatically inactive Cas9 polypeptide and a DNA-targeting RNA. Kits and compositions for carrying out the methods are also provided. The present disclosure provides genetically modified cells that produce Cas9; and Cas9 transgenic non-human multicellular organisms.

Provided herein include methods and compositions for effecting a targeted genetic change in DNA in a cell. Certain aspects and embodiments relate to improving the efficiency of the targeting of modifications to specific locations in genomic or other nucleotide sequences. As described herein, nucleic acids which direct specific changes to the genome may be combined with various approaches to enhance the availability of components of the natural repair systems present in the cells being targeted for modification.

Provided herein are methods and compositions for genetically engineering a cell (e.g., a hematopoietic cell) using CRISPR / Cas systems and homology-directed repair, genetically engineered cells produced by such methods, and methods involving administering such genetically engineered cells to a subject, such as a subject having a genetic disease.

The invention provides an anti-tumor modification method of stem / progenitor cell-derived neutrophil, which comprises the following steps: extracting mouse bone marrow-derived Lin-progenitor cells and human umbilical cord hematopoietic stem / progenitor cells, modifying ER-Hoxb8 progenitor cells by gene editing, and inducing the ER-Hoxb8 progenitor cells into neutrophil; three modification strategies of chimeric antigen receptor CAR gene engineering modification, high expression MET gene modification and high expression of IFN-gamma while the TGFBR2 gene is stably knocked out are respectively adopted, and the anti-tumor phenotype of the neutrophil N1 is maintained. Compared with the prior art, the engineering neutrophile granulocyte has the following advantages that the engineering neutrophile granulocyte prepared by the method has the advantages of infinite sources, long-time preservation, safety, controllability, efficient and rapid preparation and the like; the engineered neutrophil can maintain the N1 antitumor phenotype and promote the antitumor function; the immunosuppression microenvironment of the solid tumor can be improved and the treatment effect can be improved by singly using or combining the immune checkpoint inhibitor.

The invention provides to improved methods for the modification of genes in plant cells, and plants and seeds derived therefrom. More specifically, the invention relates to the increased efficiency of targeted gene mutation by combining gene repair oligonucleotides with approaches that enhance the availability of components of the target cell gene repair mechanisms.

The invention provides an application of a mesenchymal stem cell modified by an IGF-1 (Insulin-like Growth Factor 1) gene in treatment of premature ovarian failure. The invention provides a modified IGF-1mRNA (Insulin-like Growth Factor). The modified IGF-1mRNA comprises a 5'end capping structure (Cap) and a 3 '-polyA tailed structure of an RNA (Ribonucleic Acid) sequence, and encapsulating the modified IGF-1 mRNA (messenger Ribonucleic Acid) by using an ionizable lipid. The invention further provides a preparation method of the liposome based on the ionizable lipid, a method for improving the transfection efficiency of the IGF-1 in-vitro transfected mesenchymal stem cells and the IGF-1 transfected mesenchymal stem cells obtained by adopting the method, MSCs are promoted to continuously and stably express IGF-1, the MSCs can stably secrete factors to promote cell proliferation and differentiation, and the granular cell secretion activity is maintained. The IGF-1 transfected mesenchymal stem cells can be used for preparing a medicine for treating premature ovarian failure, the IGF-1 modified MSCs can assist the premature ovarian failure in recovery, and the technical problem that the treatment effect cannot be improved due to the fact that the dosage of the MSCs is limited in the clinical treatment process can be solved.